Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that results from the Phase 1b clinical study of its Nectin-4–targeting ADC 9MW2821 (Bulumtatug Fuvedotin, “BFv”) in patients with ADC-pretreated advanced triple-negative breast cancer have been selected for an oral presentation at the 2026 San Antonio Breast Cancer Symposium (SABCS). As one of the largest and most influential international academic meetings in the field of breast cancer, SABCS will take place this year on December 8–11 in San Antonio, Texas, USA.

Oral Presentation

Presentation Title: Efficacy and safety of bulumtatug fuvedotin (BFv, 9MW2821), a Nectin-4 antibody-drug conjugate (ADC), in patients with advanced triple-negative breast cancer (aTNBC) previously treated with antibody-drug conjugates (ADCs): a phase Ib dose optimization study (9MW2821-CP103).

Presentation Number: RF4-4

Speaker: Nour Abuhadra，Memorial Sloan Kettering Cancer Center

Session: Rapid Fire 4

Session Date and Time: December 9, 2026, 5:30 PM - 6:30 PM

Location: Stars at Night 1-2